MAPT and Alzheimer disease: Alzheimer's disease (AD) affects 5% of people over age 65 years, and its prevalence is increasing.1 Although AD manifests amyloid plaques and tau tangles, loss of synapses, eventually accompanied by neuronal loss, more closely correlates with cognitive decline.2 Damage to neurons occurs at least partially through generation of oxidative and nitrosative stress, due to excessive generation of reactive oxygen/nitrogen species (ROS/RNS) triggered by oligomeric amyloid-β (Aβ) peptide.3, 4, 5, 6